In direct compression campaigns for veterinary tablets, the botanical powder is first screened through a 710 µm sieve and dry-blended with microcrystalline cellulose, croscarmellose sodium, and a colloidal silicon dioxide glidant in a bin blender at 12 rpm for 20 min. The blend is discharged into a rotary tablet press equipped with a forced feeder; compression force is adjusted within 8–14 kN to achieve target hardness because elastic recovery of the fibrous lignocellulose fraction causes capping when compression speed exceeds 45 rpm on a 16-station press. Lubrication with magnesium stearate is limited to 0.25–0.75% w/w and is added in the final 3 min to avoid excessive hydrophobicity that retards disintegration. Disintegration time is tested per USP <701> and is typically controlled to not more than 15 min for immediate-release veterinary tablets. Uniformity of dosage units is assessed per USP <905>, and the batch is released against a marker compound HPLC assay with acceptance limits derived from the certificate of analysis of the specific botanical batch. If residual moisture of the incoming powder exceeds 5.0% w/w, dry granulation by roller compaction is substituted to avoid picking and sticking on the lower punch face. Published data for this specific botanical configuration under direct compression on high-speed presses is limited; therefore each commercial die table set is qualified with a trial run of not less than 30 min before main compression.

What limits fill weight uniformity when the botanical powder is filled into hard capsules without pre-compaction?

On a dosator-type capsule filler, the principal constraint is the transition from bulk powder to dosator slug under low compression, where cohesive bridging and air entrainment produce variable slug mass. Powder flow is assessed per USP <1174>; an angle of repose exceeding 40° or a Hausner ratio above 1.35 indicates that a pre-compaction step or glidant adjustment is required before automatic encapsulation. When tamping pin stations are used, the number of tamps must be increased if the tapped density of the blend falls below 0.40 g/mL, but over-tamping densifies the fill and retards capsule disintegration. The formulation is prepared with pregelatinised starch and sodium lauryl sulfate at 0.1–0.3% w/w to reduce electrostatic adhesion of the botanical fines to stainless steel contact parts. Fill weight variation is monitored gravimetrically and evaluated against USP <905> for uniformity of dosage units, while capsule shell moisture is held at 13–15% w/w because shell brittleness and splitting occur below 12% w/w on high-speed filling lines. The capsule band or sealing step is performed within 30 min of filling to limit moisture exchange between the shell and the botanical powder. If the raw powder batch contains volatile oil residues, the filled capsules are stored in sealed high-density polyethylene drums at or below 25°C before blistering.

Before a parenteral batch can proceed to terminal sterilisation, the extractable fraction of the powder is dissolved in Water for Injection at 60–80°C and clarified through a 0.45 µm membrane, followed by a 0.22 µm sterilising-grade filter. The clarified solution is tested for bacterial endotoxins per USP <85> and visible particulates per USP <790>; because the raw botanical matrix carries natural lipopolysaccharide content, depyrogenation is usually achieved by depth filtration or activated carbon rather than by dry heat, which would degrade the chlorogenic acid marker. Terminal autoclaving at 121°C for 15 min is considered only when the marker assay shows stability across the full F₀ accumulation; otherwise aseptic filtration is selected and the sterilised filtrate is filled into glass ampoules or vials. The pH is adjusted with dilute hydrochloric acid or sodium hydroxide between 5.5 and 7.0, because precipitation risk of coumarin-type aglycones is pH-dependent and must be screened across the range 4.0–8.0. Residual ethanol from any upstream hydroalcoholic extraction is controlled per ICH Q3C. The final injection must meet sterility testing per USP <71> and endotoxin limits appropriate for the target species; published data for this specific botanical parenteral formulation is limited, and each new formulation is subjected to a forced degradation study at 40°C/75% RH for 10 days to establish a preliminary shelf-life.

Wet granulation water activity thresholds and binder selection cannot be considered independently of residual botanical matrix

When fluid-bed granulation is used, the powder is mixed with lactose monohydrate and maize starch, then sprayed with 5% w/w polyvinylpyrrolidone K30 solution at inlet air temperature 55–65°C. The endpoint is controlled by loss on drying per USP <731> and not by visual observation alone; a target water activity below 0.60 is required to suppress mould growth, while excessive drying below 1.5% w/w moisture causes granule friability and dust generation during subsequent coating or blending. Screening through 20 mesh (840 µm) after drying normalises granule size, and oversized material is milled through a conical mill at 1200 rpm to avoid excessive fines. If the binder solution is sprayed too rapidly, marker migration to the granule surface produces colour mottling and variable content uniformity; this failure is detected by assay of three stratified samples across the dryer bowl. Granule flow is measured per USP <1174>, and the final granulate is compressed on a rotary press only when the angle of repose is below 35°. The use of reducing sugars as carriers is avoided because the botanical matrix contains nitrogenous constituents that can undergo Maillard browning during warm storage above 30°C. Dried granules are packaged in moisture-barrier pouches after nitrogen flushing because water activity drift above 0.62 during bulk storage causes caking.

On feed mill lines where the powder is incorporated into a vitamin-mineral premix by a double-ribbon mixer, segregation risk is governed by particle size overlap between the botanical API and the carrier. Static charge generation during mixing at relative humidity below 40% causes agglomeration on metal surfaces; the powder is therefore conditioned to 15–25% RH before blending. Mixer validation follows ISO 6497:2005 sampling guidance, with total batch coefficient of variation not more than 5% for marker assay. Carry-over is assessed after flushing with a quantity of ground corn or rice hulls determined by mixer capacity, and the cleaning endpoint is evaluated by visual inspection under UV light at 365 nm because residual chlorophyll fluorescence remains detectable after blank dusting. At high inclusion rates above 5% w/w of premix, the powder can reduce flow through bin slides and elevators due to its fibrous fraction; level sensors and air cannons are commissioned during worst-case high-humidity conditions. Published data for this specific botanical premix at commercial inclusion rates is limited; dose confirmation in target species under farm conditions is required before any label claim.

When a clear drinking water solution is required, water quality and preservative loading become release-test variables

In drinking water medication, the aqueous extract is prepared by heating in water at 80–90°C for 30–45 min, then cooling and separating the supernatant. The extract is standardised on marker content and diluted into water lines; hardness, pH, and microbial bioburden of farm water affect stability. Alkaline water above pH 8.0 accelerates oxidative degradation of chlorogenic acid, while excessive carbonate hardness precipitates calcium salts of polyphenolic acids. Preservative systems based on sodium benzoate at 0.1% w/w require pH below 5.5 to maintain benzoic acid activity; where target animals reject acidified water, potassium sorbate or citric acid blends are assessed by palatability tests under blinded intake comparisons. The solution is packaged in high-density polyethylene containers with light protection because photodegradation of flavonoid components occurs within 24 h under direct sunlight. Turbidity and particle count are checked after 24 h storage to confirm no precipitation from hard water, and the final solution is assayed for marker content rather than only pH and appearance. Published data for this specific botanical solution in target species drinking water is limited; each farm water supply is tested for chlorine demand before setting the preservative loading.

Direct powder sachets for oral administration present a different loading constraint: the API is blended with lactose monohydrate and colloidal silicon dioxide at a controlled temperature below 25°C and relative humidity below 40% to limit agglomeration. The blend is filled into aluminium foil sachets with a heat-seal lapping film; headspace oxygen is reduced to below 2% through nitrogen flushing when the sachet material is not an oxygen barrier. Filling equipment is calibrated gravimetrically, and the powder is tested for aerobic plate count per ISO 4833-1:2013, absence of Salmonella in 25 g per ISO 6579-1:2017, and total yeast and mould per ISO 21527-1:2008. Blending time is constrained by static charge because over-blending beyond 30 min in a V-blender raises powder temperature and reduces content uniformity due to particle segregation. No terminal drying is applied, so incoming moisture from the API is critical; if moisture exceeds 5.0% w/w, a drying step at 45°C for 4 h is inserted before final sachet filling. The sachets are then conditioned for 24 h under ambient warehouse conditions before cartoning to detect seal leakage through weight gain or marker assay drift.